Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (538)	4/28/1999 9:58:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

I may have posted this already...but did not want to leave the thread on a down note:-) \| SYMPOSIA \| DAY 8:50 Specificity and Generality in Chemical Genetic Research Stuart L. Schreiber, Ph.D., Co-Director, Harvard Institute of Chemistry & Cell Biology, Harvard University Transcription profiling using DNA chips allows the specificity of small molecules to be assessed in a semi-quantitative way for the first time. We have used this method to show that the specificity of a small molecule approaches that of a deletion mutant, where the gene encoding the small molecule receptor is inactivated. Chemical genetic studies aimed at exploring signal transduction, the role of chromatin in gene regulation and the role of PIK-related kinases in cell cycle checkpoints are underway. We have undertaken two approaches to generalize chemical genetics. One approach uses small molecule dimerizers, which allow for the study of function of proteins for which small molecule ligands are not known. The second approach uses our ability to emulate many aspects of genetic principles to discover small molecule ligands, which could lead to a small molecule partner for every gene product. drugdisc.com

To: Mike McFarland who wrote (538)	5/1/1999 11:41:00 PM
From: Gunter RICHTER	Respond to of 4474

Yes, you did sneak a peek into the future: a real pharmaceutical company will eventually transform ARIA research into money. Now, since the market knows ARIA can't do it, the game is now to let ARIA bleed to death so it won't have any bargaining power in selling off it's assets.It will all be swallowed up pretty cheap. AND DON'T FORGET THE ACCOUNTING PART OF THE LIQUIDATION EQUATION: there will be so many senior claims pulled out of the drawer against ARIA assets ( salaries,bonuses,research collaboration fees, backdoor agreements with funding partners etc,etc)that common equity will be go virtually unsatisfied. I speak from experience. In the big equity graveyard there are many markers with names like ARIA- and guess what, they all died the same way. No surprise to any sharp mind in the field. Adios Amigo.